Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

NCT ID: NCT00351858

Last Updated: 2015-05-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2009-02-28

Brief Summary

The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer

Detailed Description

A multi-centre, phase II study of ertumaxomab in metastatic breast cancer patients who became progressive after hormonal therapy. Each eligible patient will receive three ascending doses of ertumaxomab, administered intravenously. Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days. Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive.

Conditions

Breast Neoplasms; Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

ertumaxomab

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Female gender, and if of child-bearing potential must have negative pregnancy test result within 2 days before enrolment and must agree to practice effective birth control during the study.
• Aged 18 years and older.
• Histologically or cytologically confirmed invasive breast cancer with stage IIIb or IV disease with documented progression.
• Measurable disease according to RECIST.
• Histologically documented advanced primary breast cancer or biopsy of metastatic site demonstrating HER-2/neu expression (HER-2/neu 1+ or 2+, determined by immunohistochemistry [IHC]). HER-2/neu 2+ patients must have a negative Fluorescence In Situ Hybridization [FISH] test result.
• Hormone receptor status Estrogen Receptors (ERs) positive and/or Progesterone Receptors (PRs) positive.
• No prior treatment with mouse or rat antibodies.
• Life expectancy of at least six months (if the life expectancy of a patient is unspecified she will be allowed to enter the study).
• An Eastern Cooperative Oncology Group (ECOG) performance score of £ 1.
• Patients must have had disease progression after hormonal therapy including at least one aromatase inhibitor.
• Adequate hematological, liver and kidney function:

• Thrombocytes ³ 100000 / mm³ (= 100 x 109 /l)
• Hemoglobin ³ 10 g/dl
• Neutrophil count ³ 1500/mm³ (= 1.5 x 109 /l)
• WBC ³ 3 X 109 /l
• Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) ≤ 2.5 x upper limit of normal (ULN)
• Serum bilirubin ≤ 2 x ULN
• Creatinine ≤ 1.5 x ULN or clearance ³ 60 ml/min
• No life-threatening visceral disease.
• No known brain or central nervous system metastases.
• No symptomatic pleural effusions.
• No symptomatic pericardial effusions.
• No subjects whose only site of metastatic involvement is bone metastases with the exception of those with a measurable soft tissue component of the bone lesion seen with imaging that does not require palliative radiation intervention and/or the patient has a lytic bone lesion ³ 1 cm measured with radiography that can be followed for evidence of re-calcification.
• No history of relevant cardiovascular disease:

• LVEF within the institutional ranges of normal as measured by echocardiogram or MUGA scan
• No prior uncontrolled or symptomatic congestive heart failure NYHA ³ 2
• No myocardial infarction within the past two years
• No uncontrolled or symptomatic cardiac arrhythmias
• No severe dyspnea.
• No pulmonary dysfunction or need for continuous supportive oxygen inhalation.
• No other concurrent uncontrolled co-morbid illness.
• No other concurrent malignancy, except treated basal cell or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix.
• Patients with documented autoimmune diseases (such as lupus) are excluded from participation in the study unless a waiver is granted by the responsible medical monitor.
• Patients with a human immunodeficiency virus, hepatitis B or hepatitis C positive status are excluded from participation in the study.
• No prior or concurrent chemotherapy regimen for advanced or metastatic disease.
• Prior neo-adjuvant or adjuvant chemotherapy is allowed provided it was stopped at least six months before study entry.
• No concurrent hormone therapy (hormone therapy must be stopped at the screening visit).
• At least 4 weeks since prior radiotherapy.
• No concurrent immune therapy.
• No concurrent corticosteroid therapy.
• No regularly used medication for a health condition or comorbidity that might result in undue risk to the patient.
• No prior investigational treatment for advanced or metastatic disease.
• Able and willing to comply fully with the protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Neovii Biotech

INDUSTRY

Sponsor Role: lead

Principal Investigators

Fatima Cardoso, MD

Role: PRINCIPAL_INVESTIGATOR

Brussels

Locations

Jules Bordet Institute, Free University of Brussels

Brussels, , Belgium

Countries

Belgium

References

Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A, Korfel A, Jager M, Lindhofer H, Sommer H, Thiel E, Untch M. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006 May 15;12(10):3085-91. doi: 10.1158/1078-0432.CCR-05-2436.

Reference Type: BACKGROUND

PMID: 16707606 (View on PubMed)

Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995 Jul 1;155(1):219-25.

Reference Type: BACKGROUND

PMID: 7602098 (View on PubMed)

Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999 Aug 1;163(3):1246-52.

Reference Type: BACKGROUND

PMID: 10415020 (View on PubMed)

Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000 Jul;83(2):261-6. doi: 10.1054/bjoc.2000.1237.

Reference Type: BACKGROUND

PMID: 10901380 (View on PubMed)

Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001 Oct 15;98(8):2526-34. doi: 10.1182/blood.v98.8.2526.

Reference Type: BACKGROUND

PMID: 11588051 (View on PubMed)

Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A. TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res. 2001 Sep-Oct;21(5):3499-503.

Reference Type: BACKGROUND

PMID: 11848515 (View on PubMed)

Other Identifiers

EudraT number: 2005-004294-21

Identifier Type: -

Identifier Source: secondary_id

FBT-IVREXBC 02

Identifier Type: -

Identifier Source: org_study_id